Skip to Content

Biotest AG ADR BTTAY

Morningstar Rating
Unlock our analysis with Morningstar Investor

About Quantitative Ratings

Morningstar Quantitative Ratings for Stocks are generated using an algorithm that compares companies that are not under analyst coverage to peer companies that do receive analyst-driven ratings. Companies with quantitative ratings are not formally covered by a Morningstar analyst, but are statistically matched to analyst-rated companies, allowing our models to calculate a quantitative moat, fair value, and uncertainty rating.

Price vs Fair Value

BTTAY is trading at a 42% premium.
Price
$24.14
Fair Value
$26.56
Uncertainty
Extreme
1-Star Price
$95.24
5-Star Price
$14.36
Economic Moat
Ljcxrfh
Capital Allocation
Is it the right time to buy, sell, or hold?
Start a free trial of Morningstar Investor to unlock exclusive ratings and continuous analyst coverage to help you decide if BTTAY is a good fit for your portfolio.

Trading Information

Previous Close Price
Day Range
$24.2724.27
52-Week Range
$24.2724.27
Bid/Ask
$16.93 / $382.12
Market Cap
$1.92 Bil
Volume/Avg
3,070 / 3,070

Key Statistics

Price/Earnings (Normalized)
Price/Sales
3.38
Dividend Yield (Trailing)
Dividend Yield (Forward)
Total Yield

Company Profile

Biotest AG is a supplier of biological medicines. The company produces its products from human blood plasma or manufactured by using biotechnology methods. It is engaged in the area of hematology, clinical immunology, and intensive care medicine. The operating business segments are Therapy, Plasma and Services, and Other segments. It generates maximum revenue from the Therapy segment. Geographically, it derives a majority of revenue from Central Europe and also has a presence in other countries.
Sector
Healthcare
Industry
Biotechnology
Stock Style Box
Small Growth
Total Number of Employees
2,426

Comparables

Valuation

Metric
BTTAY
VVY
NYKD
Price/Earnings (Normalized)
Price/Book Value
5.132.122.88
Price/Sales
3.3841.59
Price/Cash Flow
142.88
Price/Earnings
BTTAY
VVY
NYKD

Financial Strength

Metric
BTTAY
VVY
NYKD
Quick Ratio
0.889.148.43
Current Ratio
2.049.378.43
Interest Coverage
5.92−517.82
Quick Ratio
BTTAY
VVY
NYKD

Profitability

Metric
BTTAY
VVY
NYKD
Return on Assets (Normalized)
13.98%−67.58%−18.26%
Return on Equity (Normalized)
41.79%−77.07%−23.64%
Return on Invested Capital (Normalized)
19.73%−78.19%−26.98%
Return on Assets
BTTAY
VVY
NYKD
See how this stock stacks up to its competitors with Morningstar Investor

Biotechnology Industry Comparables

1-Day Chart
Name
Price
Morningstar Rating for Stocks
Capital Allocation
Economic Moat
Market Cap
Novo Nordisk A/S ADR
NVO
JqndxqchjNjvm$637.8 Bil
Vertex Pharmaceuticals Inc
VRTX
XfngwtxgMnmyvz$121.6 Bil
Regeneron Pharmaceuticals Inc
REGN
SbbygvkXllntwh$115.1 Bil
Moderna Inc
MRNA
VzxqdcppWdxdx$51.5 Bil
argenx SE ADR
ARGX
XkptrhgymFqpvq$22.6 Bil
BioNTech SE ADR
BNTX
ShkwktqnNjlq$20.7 Bil
Alnylam Pharmaceuticals Inc
ALNY
GlgmrbgtcZbymt$19.9 Bil
Biomarin Pharmaceutical Inc
BMRN
RghkhgxlrHrdjzc$16.1 Bil
United Therapeutics Corp
UTHR
ZfyzfhgpFbtl$13.7 Bil
Incyte Corp
INCY
BhkfpmmKyzdt$12.3 Bil

Sponsor Center